Dopamine D2High receptors moderately elevated by sertindole

Synapse

Volumn 62, Issue 5, 2008, Pages 389-393

  Seeman, Philip ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Dopamine D2 receptor; Dopamine D2High receptor; Striatum

Indexed keywords

DOMPERIDONE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE D2 HIGH RECEPTOR; DOPAMINE RECEPTOR; HALOPERIDOL; SERTINDOLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BINDING AFFINITY; CONTROLLED STUDY; CORPUS STRIATUM; NONHUMAN; PRIORITY JOURNAL; RAT; SUPERSENSITIVITY;

ANIMALS; ANTIPSYCHOTIC AGENTS; BINDING, COMPETITIVE; DOMPERIDONE; DOPAMINE ANTAGONISTS; GUANINE NUCLEOTIDES; HALOPERIDOL; IMIDAZOLES; INDOLES; NEOSTRIATUM; OXAZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2;

EID: 41349086846     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20498     Document Type: Article

References (30)

1. Arnt J. 1998. Pharmacological differentiation of classical and novel antipsychotics. Int Clin Psychopharmacol 13(Suppl 3):S7-S14.
2. 3 H-Domperidone: A selective ligand for dopamine receptors. Naunyn-Schmiedeberg's Arch Pharmacol 308:231-237.
3. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
4. Chouinard G, Jones BD. 1980. Neuroleptic-induced supersensitivity psychosis: Clinical and pharmacologic characteristics. Am J Psychiatry 137:16-21.
5. George SR, Watanabe M, Di Paolo T, Falardeau P, Labrie F, Seeman P. 1985. The functional state of the dopamine receptor in the anterior pituitary is in the high-affinity form. Endocrinology 117:690-697.
6. 3H]-Domperidone labels only a single population of receptors which convert from high to low affinity for dopamine in rat brain. Naunyn-Schmiedeberg's Arch Pharmacol 332:21-25.
7. Hyttel J, Nielsen JB, Nowak G. 1992. The acute effect of sertindole on brain 5-HT2, D2 and α 1 receptors (ex vivo radioreceptor binding studies). J Neural Transm Gen Sect 89:61-69.
8. Kapur S, VanderSpek SC, Brownlee BA, Nobrega JN. 2003. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: A suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305:625-631.
9. Lambert TJ. 2007. Switching antipsychotic therapy: What to expect and clinical strategies for improving therapeutic outcomes. J Clin Psychiatry 68:10-13.
10. 3H-domperidone binding and its displacement by dopamine in rat striatal homogenates. J Recept Res 3:163-175.
11. Martres MP, Sokoloff P, Schwartz J-C. 1984. Dopaminergic binding sites in rat striatal slices and the action of guanyl nucleotides. Naunyn-Schmiedeberg's Arch Pharmacol 325:116-123.
12. McDonald WM, Sibley DR, Kilpatrick BF, Caron MG. 1984. Dopaminergic inhibition of adenylate cyclase correlates with high affinity agonist binding to anterior pituitary D2 dopamine receptors. Mol Cell Endocrinol 36:201-209.
13. Muller P, Seeman P. 1978. Dopaminergic supersensitivity after neuroleptics: Time-course and specificity. Psychopharmacology 60:1-11.
14. Samaha A-N, Seeman P, Stewart J, Rajabi H, Kapur S. 2007a. "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci 27:2979-2986.
15. Samaha A-N, Reckless GE, Seeman P, Kapur S. 2007b. Continuous but not intermittent haloperidol treatment leads to dopamine supersensitivity and a progressive loss in antipsychotic efficacy. In: Dopamine 50 years later. Abstracts International Meeting, Göteborg, 2007.
16. Sánchez C, Arnt J, Dragsted N, Hyttel J, Lembøl HL, Meier E, Perregaard J, Skarsfeldt T. 1991. Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound. Drug Dev Res 22:239-250.
17. Seeman P. 1980. Brain dopamine receptors. Pharmacol Rev 32:229-313.
18. Seeman P. 2006. Targeting the dopamine D2 receptor in schizophrenia. Expert Opin Ther Targets 10:515-531.
19. High receptors. Synapse 61:1013-1018.
20. 3H-spiperone depend on tissue concentration: analysis and examples. J Neurochem 43:221-235.
21. Seeman P, Ulpian C, Larsen RD, Anderson PS. 1993. Dopamine receptors labelled by PHNO. Synapse 14:254-262.
22. 3H] spiperone in isotonic medium: Implications for human positron emission tomography. Synapse 49;209-215.
23. High states, implying many paths to psychosis. Proc Natl Acad Sci USA 102:3513-3518.
24. High receptors. Synapse 58:122-128.
25. High dopamine receptors. Synapse 60:319-346.
26. 3H](+)PHNO. Synapse 61:263-267.
27. Seeman P, Ko F, Jack E, Greenstein R, Dean B. 2007b. Consistent with dopamine supersensitivity, RGS9 expression is diminished in the amphetamine-treated animal model of schizophrenia and in post-mortem schizophrenia brain. Synapse 61:303-309.
28. Sibley DR, De Lean A, Creese I. 1982. Anterior pituitary dopamine receptor. Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor. J Biol Chem 257:6351-6361.
29. 3H-domperidone binding sites differ in rat striatum and pituitary. Naunyn-Schmiedeberg's Arch Pharmacol 327:221-227.
30. Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, Sebree TB, Wallin BA, Kashkin KB. 1997. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 154:782-791.